Wall Street brokerages expect Paratek Pharmaceuticals Inc (NASDAQ:PRTK) to post ($0.72) earnings per share (EPS) for the current quarter, according to Zacks Investment Research. Three analysts have made estimates for Paratek Pharmaceuticals’ earnings, with estimates ranging from ($0.88) to ($0.56). Paratek Pharmaceuticals reported earnings per share of ($1.16) in the same quarter last year, which suggests a positive year over year growth rate of 37.9%. The business is expected to report its next earnings report on Thursday, March 1st.

On average, analysts expect that Paratek Pharmaceuticals will report full year earnings of ($3.32) per share for the current fiscal year, with EPS estimates ranging from ($3.78) to ($3.05). For the next year, analysts expect that the firm will post earnings of ($3.33) per share, with EPS estimates ranging from ($4.43) to ($2.51). Zacks’ EPS averages are a mean average based on a survey of sell-side analysts that follow Paratek Pharmaceuticals.

A number of research analysts have weighed in on the stock. Cantor Fitzgerald reiterated a “buy” rating and issued a $50.00 price objective on shares of Paratek Pharmaceuticals in a research report on Thursday, September 21st. Robert W. Baird reiterated a “buy” rating and issued a $40.00 price objective on shares of Paratek Pharmaceuticals in a research report on Tuesday, October 24th. ValuEngine downgraded shares of Paratek Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Monday, September 18th. Raymond James Financial reiterated a “strong-buy” rating and issued a $36.00 price objective on shares of Paratek Pharmaceuticals in a research report on Thursday, August 24th. Finally, BidaskClub downgraded shares of Paratek Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Wednesday, August 23rd. Two equities research analysts have rated the stock with a sell rating, one has assigned a hold rating, six have given a buy rating and one has given a strong buy rating to the company. The company currently has an average rating of “Buy” and a consensus price target of $40.00.

Several institutional investors and hedge funds have recently added to or reduced their stakes in PRTK. Alyeska Investment Group L.P. raised its position in shares of Paratek Pharmaceuticals by 473.4% during the 3rd quarter. Alyeska Investment Group L.P. now owns 916,349 shares of the specialty pharmaceutical company’s stock worth $23,000,000 after purchasing an additional 756,535 shares during the last quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS acquired a new position in shares of Paratek Pharmaceuticals during the 3rd quarter worth about $8,598,000. State Street Corp raised its position in shares of Paratek Pharmaceuticals by 112.3% during the 2nd quarter. State Street Corp now owns 616,112 shares of the specialty pharmaceutical company’s stock worth $14,850,000 after purchasing an additional 325,856 shares during the last quarter. Pictet Asset Management Ltd. raised its position in shares of Paratek Pharmaceuticals by 90.8% during the 3rd quarter. Pictet Asset Management Ltd. now owns 661,995 shares of the specialty pharmaceutical company’s stock worth $16,616,000 after purchasing an additional 315,010 shares during the last quarter. Finally, Davidson Kempner Capital Management LP acquired a new position in shares of Paratek Pharmaceuticals during the 3rd quarter worth about $6,727,000. Hedge funds and other institutional investors own 84.30% of the company’s stock.

Shares of Paratek Pharmaceuticals (PRTK) traded down $0.05 during trading on Wednesday, hitting $17.80. 73,478 shares of the company’s stock were exchanged, compared to its average volume of 572,830. Paratek Pharmaceuticals has a 1-year low of $13.15 and a 1-year high of $29.00. The company has a debt-to-equity ratio of 0.49, a current ratio of 10.53 and a quick ratio of 10.53.

ILLEGAL ACTIVITY NOTICE: This report was first published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this report on another domain, it was illegally copied and republished in violation of US and international trademark & copyright legislation. The correct version of this report can be viewed at https://www.thecerbatgem.com/2017/12/20/analysts-anticipate-paratek-pharmaceuticals-inc-prtk-will-announce-earnings-of-0-72-per-share.html.

About Paratek Pharmaceuticals

Paratek Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics based upon tetracycline chemistry. Its product candidates are the antibacterials omadacycline and sarecycline. Omadacycline is an antibiotic being developed for use as an empiric monotherapy option for patients suffering from serious, community-acquired bacterial infections.

Get a free copy of the Zacks research report on Paratek Pharmaceuticals (PRTK)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Paratek Pharmaceuticals (NASDAQ:PRTK)

Receive News & Ratings for Paratek Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Paratek Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.